Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib in ROS1-positive advanced NSCLC
NCT03608007Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Primary endpoint: Objective Response Rate at 12 weeks. Status: unknown.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03608007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608007.